with cirrhosis. 2 , 6 , 7 The goals of surveillance are to detect HCC at an early stage when it is amenable to curative therapy and to reduce all-cause mortality. 8 Effective implementation of the screening process requires surveillance (obtaining an
Search Results
Screening Process Failures for Hepatocellular Carcinoma
Amit G. Singal, Jorge A. Marrero, and Adam Yopp
Colorectal Cancer Screening, Version 1.2015
Dawn Provenzale, Kory Jasperson, Dennis J. Ahnen, Harry Aslanian, Travis Bray, Jamie A. Cannon, Donald S. David, Dayna S. Early, Deborah Erwin, James M. Ford, Francis M. Giardiello, Samir Gupta, Amy L. Halverson, Stanley R. Hamilton, Heather Hampel, Mohammad K. Ismail, Jason B. Klapman, David W. Larson, Audrey J. Lazenby, Patrick M. Lynch, Robert J. Mayer, Reid M. Ness, M. Sambasiva Rao, Scott E. Regenbogen, Moshe Shike, Gideon Steinbach, David Weinberg, Mary A. Dwyer, Deborah A. Freedman-Cass, and Susan Darlow
, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for Colorectal Cancer Screening Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Colorectal Cancer
Implementation of NCCN Distress Management Guidelines by Member Institutions
Paul B. Jacobsen and Sean Ransom
The authors have no financial interest, arrangement, or affiliation with the manufacturers of any products discussed in the article or their competitors. References 1. Hoffman BM Zevon MA D'Arrigo MC . Screening for distress
Implementing Routine Screening for Distress, the Sixth Vital Sign, for Patients With Head and Neck and Neurologic Cancers
Barry D. Bultz, Amy Waller, Jodi Cullum, Paula Jones, Johan Halland, Shannon L. Groff, Catriona Leckie, Lisa Shirt, Scott Blanchard, Harold Lau, Jacob Easaw, Konrad Fassbender, and Linda E. Carlson
/print certificate. Release date: October 25, 2013; Expiration date: October 25, 2014 Learning Objectives Upon completion of this activity, participants will be able to: Discuss the benefits that implementing a routine distress screening program had on
NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018
Dawn Provenzale, Samir Gupta, Dennis J. Ahnen, Arnold J. Markowitz, Daniel C. Chung, Robert J. Mayer, Scott E. Regenbogen, Amie M. Blanco, Travis Bray, Gregory Cooper, Dayna S. Early, James M. Ford, Francis M. Giardiello, William Grady, Michael J. Hall, Amy L. Halverson, Stanley R. Hamilton, Heather Hampel, Jason B. Klapman, David W. Larson, Audrey J. Lazenby, Xavier Llor, Patrick M. Lynch, June Mikkelson, Reid M. Ness, Thomas P. Slavin Jr, Shajanpeter Sugandha, Jennifer M. Weiss, Mary A. Dwyer, and Ndiya Ogba
for Colorectal Cancer Screening Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Colorectal Cancer Screening Disclosure of Relevant Financial Relationships The NCCN staff listed below
PSA Screening for Prostate Cancer: Why Saying No is a High-Value Health Care Choice
Timothy J. Wilt and Philipp Dahm
Few health issues have produced more controversy than prostate-specific antigen (PSA) screening for prostate cancer. Screening and early treatment for screen-detected disease may provide large personal and public health benefits. Prostate cancer
Survivorship: Screening for Cancer and Treatment Effects, Version 2.2014
Crystal S. Denlinger, Jennifer A. Ligibel, Madhuri Are, K. Scott Baker, Wendy Demark-Wahnefried, Don Dizon, Debra L. Friedman, Mindy Goldman, Lee Jones, Allison King, Grace H. Ku, Elizabeth Kvale, Terry S. Langbaum, Kristin Leonardi-Warren, Mary S. McCabe, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Mary Ann Morgan, Javid J. Moslehi, Tracey O’Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, Muhammad Raza, M. Alma Rodriguez, Karen L. Syrjala, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole R. McMillian, and Deborah A. Freedman-Cass
appropriate. All recommendations are category 2A unless otherwise noted. Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. Screening for
Financial Toxicity and Its Association With Prostate and Colon Cancer Screening
Michael J. Herriges Jr, Rachel Shenhav-Goldberg, Juliet I. Peck, Sumeet K. Bhanvadia, Alicia Morgans, Fumiko Chino, Thenappan Chandrasekar, Oleg Shapiro, Joseph M. Jacob, Alina Basnet, Gennady Bratslavsky, and Hanan Goldberg
children. Financial toxicity has been linked to delaying or forgoing cancer care after diagnosis. 12 – 14 However, little is known about the effect of financial toxicity on cancer prevention. Delaying recommended cancer screenings can potentially increase
Screening Performance for Frailty Among Older Patients With Cancer: A Cross-Sectional Observational Study of Two Approaches
Toru Okuyama, Koji Sugano, Shinsuke Iida, Takashi Ishida, Shigeru Kusumoto, and Tatsuo Akechi
Guidelines in Oncology (NCCN Guidelines) for Older Adult Oncology 13 recommend screening older patients with cancer for frailty using screening tools (to view the most recent version of these NCCN Guidelines, visit NCCN.org ). The Vulnerable Elders Survey
Update on PSA Testing
Mark L. Gonzalgo and H. Ballentine Carter
-confined prostate cancer is increased through prostate-specific antigen-based screening . JAMA 1993 ; 270 : 948 – 954 . 2. Catalona WJ Richie JP Ahmann FR . Comparison of digital rectal examination and serum prostate specific antigen in the early